Allos announced today that it has held a meeting with the U.S. Food and Drug Administration (FDA) to optimize the design of their Phase 3 trial.
Read More
Allos announced presentation of “Arbaclofen produces clinically meaningful improvements in individuals with Fragile X” at the 18th NFXF International Fragile X Conference, July 14-17th, 2022.
Allos announced the exclusive license rights on arbaclofen in Fragile X Syndrome (FXS). The company is preparing the regulatory path for market authorization.
